[119th Congress Public Law 138]
[From the U.S. Government Publishing Office]
[[Page 140 STAT. 1104]]
Public Law 119-138
119th Congress
An Act
To amend the Accelerating Access to Critical Therapies for ALS Act to
reauthorize the provisions of such Act through fiscal year 2031, and for
other purposes. <<NOTE: Nov. 3, 2026 - [H.R. 8205]>>
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled, <<NOTE: Accelerating
Access to Critical Therapies for ALS Reauthorization Act of 2026.>>
SECTION 1. <<NOTE: 21 USC 301 note.>> SHORT TITLE.
This Act may be cited as the ``Accelerating Access to Critical
Therapies for ALS Reauthorization Act of 2026''.
SEC. 2. REAUTHORIZATION OF ACCELERATING ACCESS TO CRITICAL
THERAPIES FOR ALS ACT.
(a) In General.--Section 7 of the Accelerating Access to Critical
Therapies for ALS Act (Public Law 117-79) <<NOTE: 135 Stat. 1538.>> is
amended by striking ``2026'' and inserting ``2031''.
(b) Grants for ALS Research.--Section 2(f) of the Accelerating
Access to Critical Therapies for ALS Act (21 U.S.C. 360ee note) is
amended by striking ``2026'' and inserting ``2031''.
SEC. 3. IMPROVEMENTS TO PROGRAM FOR GRANTS FOR RESEARCH ON
THERAPIES FOR ALS.
(a) Renewal of Grants for Research on Therapies for ALS Review.--
Section 2(b) of the Accelerating Access to Critical Therapies for ALS
Act (21 U.S.C. 360ee note) is amended by adding at the end the
following:
``(4) Renewal of grants for research on therapies for als
review. <<NOTE: Assessment. Data.>> --In reviewing applications
for renewals of a grant awarded under this section with respect
to an investigational drug, the Secretary shall request from the
manufacturer or sponsor, and assess, the enrollment, safety, and
any available efficacy data relating to the investigational drug
in the prevention, diagnosis, mitigation, treatment, or cure of
amyotrophic lateral sclerosis.''.
(b) Reporting Safety Data.--Section 2(c) of the Accelerating Access
to Critical Therapies for ALS Act (21 U.S.C. 360ee note) is amended--
(1) in paragraph (2)(B), by striking ``and'' at the end;
(2) in paragraph (3), by striking the period at the end and
inserting ``; and''; and
(3) by adding at the end the following:
``(4) <<NOTE: Compliance.>> the entity seeking such grant
will promptly report any new and serious adverse events and
safety information that is considered to be unexpected with
respect to the phase 3 trial to the grant-making institution, in
addition to complying with the safety reporting requirements
under section 312.32
[[Page 140 STAT. 1105]]
of title 21, Code of Federal Regulations (or any successor
regulations).''.
(c) Clarifying Participating Clinical Trial Definition.--Section
2(e) of the Accelerating Access to Critical Therapies for ALS Act (21
U.S.C. 360ee note) is amended by adding at the end the following:
``(4) <<NOTE: Determination.>> The term `phase 3', with
respect to a clinical trial, includes a phase 2/3 combined trial
that begins enrollment within a timeframe, determined by the
Secretary through the terms and conditions of the grant awarded
under this section.''.
SEC. 4. FDA RARE NEURODEGENERATIVE DISEASE ACTION PLAN.
Section 4 of the Accelerating Access to Critical Therapies for ALS
Act (21 U.S.C. 360aa note) is amended--
(1) in the section heading, by striking ``als and other rare
neurodegenerative disease action plan'' and inserting ``fda rare
neurodegenerative disease action plan''; and
(2) by adding at the end the following:
``(c) <<NOTE: Web postings.>> FDA Rare Neurodegenerative Disease
Action Plan.--
``(1) <<NOTE: Deadline. Time period.>> In general.--Not
later than 18 months after the date of enactment of the
Accelerating Access to Critical Therapies for ALS
Reauthorization Act of 2026, the Commissioner of Food and Drugs
shall publish on the website of the Food and Drug Administration
an action plan that includes a description of the actions that
the Food and Drug Administration intends to take during the 5-
year period following publication of the action plan with
respect to the program enhancements, policy development,
regulatory science initiatives, and other appropriate
initiatives described in subsection (a).
``(2) Report.--Not later than 5 years after the date of
enactment of the Accelerating Access to Critical Therapies for
ALS Reauthorization Act of 2026, the Commissioner of Food and
Drugs shall publish on the website of the Food and Drug
Administration a report that describes the actions taken by the
Food and Drug Administration under the action plan published
under paragraph (1) and the extent to which such action plan
meets the requirements specified in paragraph (1).''.
Approved November 3, 2026.
LEGISLATIVE HISTORY--H.R. 8205 (S. 4472):
---------------------------------------------------------------------------
HOUSE REPORTS: No. 119-733 (Comm. on Energy and Commerce).
CONGRESSIONAL RECORD, Vol. 172 (2026):
July 20, 22, considered and passed House.
Sept. 28, considered and passed Senate.
<all>